Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

S&P 500, Dow edge higher on hopes of progress in stimulus talks

10/23/2020 | 10:33am EST

(For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window.)

* Gilead up as remdesivir wins approval for treating COVID in U.S.

* Intel slumps as quarterly margins fall

* American Express drops as profit falls short of estimates

* Indexes: Dow up 0.05%, S&P up 0.09%, Nasdaq dips 0.3%

Oct 23 (Reuters) - The S&P 500 and the Dow rose on Friday, with investors expecting progress in talks on the next coronavirus aid bill as the Nov. 3 presidential election drew closer.

The Nasdaq was weighed down by a 10% slump in chipmaker Intel Corp after it reported a drop in margins as consumers bought cheaper laptops and pandemic-stricken businesses and governments clamped down on data center spending.

White House Chief of Staff Mark Meadows said late on Thursday that negotiations with lawmakers on a coronavirus relief package, now totaling $1.9 trillion, have entered a new phase.

"The stimulus talks are continuing so the market is happy about that even though we probably won't get anything done before the election," said Thomas Hayes, managing member at Great Hill Capital LLC in New York.

Uncertainty over the timeline of the relief legislature has been weighing on Wall Street's major indexes, which were set to end a choppy week slightly lower.

Meanwhile, a record 47 million Americans cast ballots, eclipsing total early voting from the 2016 election. President Donald Trump and Democratic rival Joe Biden debated on Thursday for the last time to persuade the few remaining undecided voters 12 days before their contest.

Heading into the debate, Trump trailed former vice president Biden in national polls, but the contest is much tighter in some battleground states where the election will likely be decided.

At 09:50 a.m. ET the Dow Jones Industrial Average rose 13.81 points or 0.05% to 28,377.47 and the S&P 500 gained 3.23 points or 0.09% to 3,456.72. The Nasdaq Composite lost 32.33 points or 0.28% to 11,473.68.

Third-quarter earnings season chugged along, with 84% of the 126 S&P 500 companies that have reported so far topping quarterly profit estimates, according to Refinitiv data.

Gilead Sciences Inc jumped 4% as its antiviral drug remdesivir became the first and only drug approved for treating patients hospitalized with COVID-19 in the United States.

The healthcare index added 1%, more than any other S&P sector.

American Express Co dropped 2% as it missed third-quarter profit estimates after its customers spent less during the COVID-19 fueled economic slowdown and it set aside money for potential payment defaults.

Advancing issues outnumbered decliners 2.3-to-1 on the NYSE and 1.3-to-1 on the Nasdaq.

The S&P index recorded 24 new 52-week highs and one new low, while the Nasdaq recorded 42 new highs and seven new lows. (Reporting by Medha Singh and Shivani Kumaresan in Bengaluru; Editing by Bernard Orr and Anil D'Silva)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
AMERICAN EXPRESS COMPANY 0.16% 120.58 Delayed Quote.-3.14%
DJ INDUSTRIAL -0.58% 29872.47 Delayed Quote.4.67%
GILEAD SCIENCES, INC. -1.24% 59.5 Delayed Quote.-8.43%
INTEL CORPORATION 0.09% 47.05 Delayed Quote.-21.39%
NASDAQ 100 0.60% 12152.215271 Delayed Quote.39.15%
NASDAQ COMP. 0.48% 12094.402197 Delayed Quote.34.79%
S&P 500 -0.16% 3629.65 Delayed Quote.12.35%
All news about GILEAD SCIENCES, INC.
11/25EU seeks to bypass patents to boost drugs access in crises
11/24GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23GILEAD SCIENCES : to Present at the 3rd Annual Evercore ISI HealthCONx Conferenc..
11/23Canada could approve COVID-19 vaccines early next year -regulator
11/23GILEAD SCIENCES : U.S. infectious disease group backs Gilead's remdesivir for CO..
11/21FDA Authorizes Regeneron's Covid-19 Antibody Cocktail Drug -- Update
11/20WALL STREET STOCK EXCHANGE : Stocks decline as COVID-19 cases surge
11/20NEWS HIGHLIGHTS : Top Company News of the Day
11/20Health Care Down, But Not By Much, Amid Vaccine Optimism -- Health Care Round..
11/20Post Holdings, Gilead Sciences fall; Pfizer, Hibbett rise
More news
Financials (USD)
Sales 2020 23 650 M - -
Net income 2020 34,3 M - -
Net Debt 2020 20 525 M - -
P/E ratio 2020 -4 365x
Yield 2020 4,58%
Capitalization 74 585 M 74 585 M -
EV / Sales 2020 4,02x
EV / Sales 2021 3,83x
Nbr of Employees 11 800
Free-Float 99,6%
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 73,52 $
Last Close Price 59,50 $
Spread / Highest target 76,5%
Spread / Average Target 23,6%
Spread / Lowest Target -2,52%
EPS Revisions
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Sector and Competitors
1st jan.Capitalization (M$)
WUXI APPTEC CO., LTD.56.53%37 992
BIONTECH SE209.80%25 273
GENMAB A/S55.72%24 142